Purple Biotech (PPBT) Assets Average (2014 - 2026)

Purple Biotech (PPBT) has reported Assets Average for 13 consecutive years, with $14.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 59.15% year-over-year to $14.3 million in Q2 2026; TTM through Jun 2026 was $14.3 million, a 59.15% decrease from a year earlier, with the FY2025 full-year figure at $27.3 million, down 32.86% from the prior year.
• Assets Average was $14.3 million for Q2 2026 at Purple Biotech, down from $16.0 million in the prior quarter.
• Over five years, Assets Average peaked at $68.2 million in Q1 2022 and troughed at $14.3 million in Q2 2026.
• A 5-year average of $42.4 million and a median of $40.0 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average increased 3.19% in 2025 and slumped 59.15% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $56.6 million in 2022, then decreased by 20.85% to $44.8 million in 2023, then declined by 19.46% to $36.1 million in 2024, then slipped by 21.5% to $28.3 million in 2025, then tumbled by 49.53% to $14.3 million in 2026.
• The last three Assets Average figures came in at $14.3 million (Q2 2026), $16.0 million (Q1 2026), and $28.3 million (Q4 2025), per Business Quant data.